Ikeuchi T, Kawamura N, Suzuki K, Onodera S, Osada T, Hirano A, Satomi Y, Yoshimura S, Yamamoto Y
Department of Urology, Showa University, Fujigaoka Hospital.
Hinyokika Kiyo. 1993 Jul;39(7):673-8.
In a multicenter trial at 17 institutions, the usefulness of an oral dose of 300 mg of tosufloxacin (TFLX) twice a day for 14 days were assessed in the management of chronic bacterial prostatitis (CBP) diagnosed by Meares and Stamey method. Nineteen patients who were evaluated by the UTI criteria were chosen out of the 27 patients diagnosed with CBP. The isolated bacteria from EPS were 18 species and 27 strains. In terms of MICs of isolates, TFLX gave lower MICs than any of the control drugs (CPFX, NFLX, OFLX, CCL). In particular, this tendency was clear for gram-positive coccus and anaerobes. The bacteriological elimination rate obtained for 14 strains and 19 species was 89.5% (17/19) [GPC; 75.0% (6/8), GNR; 100% (7/7), Anaerobes; 100% (4/4)]. The overall clinical efficacy by the UTI criteria was documented in 94.7% (18/19). According to the doctor's evaluation, the overall clinical efficacy rate was 68.4%. Safety evaluation revealed the development of gastrointestinal symptoms in 3 cases, which were not serious, with an incidence rate of 4.0% (3/75), while no laboratory abnormalities were observed. Transference of TFLX into the prostate is slightly lower than in other new quinolones. However, from this study we considered that the higher antibacterial activity of TFLX is one of the reasons for its usefulness for CBP.
在一项由17家机构参与的多中心试验中，评估了每日口服两次300毫克托氟沙星（TFLX），连续服用14天，用于治疗采用米尔斯和斯塔米方法诊断的慢性细菌性前列腺炎（CBP）的有效性。在27例诊断为CBP的患者中，挑选出19例根据泌尿道感染（UTI）标准进行评估的患者。从前列腺按摩液（EPS）中分离出的细菌有18种27株。就分离菌株的最低抑菌浓度（MIC）而言，TFLX的MIC低于任何一种对照药物（环丙沙星、诺氟沙星、氧氟沙星、氯林可霉素）。特别是对于革兰氏阳性球菌和厌氧菌，这种趋势很明显。对14株19种细菌的细菌学清除率为89.5%（17/19）[革兰氏阳性球菌（GPC）；75.0%（6/8），革兰氏阴性需氧菌（GNR）；100%（7/7），厌氧菌；100%（4/4）]。根据UTI标准，总体临床有效率为94.7%（18/19）。根据医生的评估，总体临床有效率为68.4%。安全性评估显示，3例出现胃肠道症状，但不严重，发生率为4.0%（3/75），同时未观察到实验室异常。TFLX向前列腺组织中的转运略低于其他新型喹诺酮类药物。然而，从本研究中我们认为，TFLX较高的抗菌活性是其对CBP有效的原因之一。
